Nicox SA (OTCMKTS:NICXF) Short Interest Down 99.9% in February

Nicox SA (OTCMKTS:NICXF) was the target of a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 21 shares, a decline of 99.9% from the February 12th total of 20,021 shares. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 0 shares, the short-interest ratio is presently ∞ days.

Nicox Stock Performance

Shares of NICXF stock remained flat at $0.30 on Tuesday. The stock has a 50-day simple moving average of $0.30 and a 200 day simple moving average of $0.30. Nicox has a 52-week low of $0.25 and a 52-week high of $0.30.

Nicox Company Profile

Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.

The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.